형광 셀 : 시장 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the fluorescence cell market size is expected to increase from USD 2.15 billion in 2025 to USD 2.29 billion in 2026 and reach USD 3.14 billion by 2031, growing at a CAGR of 6.54% over 2026-2031.

Global Fluorescence Cell Market Trends and Insights

Biomedical Research and Diagnostic Adoption: Instrumentation Grants Sustain Capital Procurement

Biomedical research continues to drive purchases in the fluorescence cells market through shared facilities and equipment grants. In July 2026, the University of Texas at Austin is expected to receive a National Institutes of Health (NIH) S10 award for a ZEISS Lightsheet 7 microscope. The system is expected to be the first light-sheet microscope in the Austin region, supporting 17 research teams and 29 NIH-sponsored projects. Shared procurement models enable multiple laboratories to access advanced instruments that may be difficult for individual laboratories to fund independently. Although clinical adoption is progressing at a slower pace, clinical certification and quality requirements can benefit established suppliers with validated systems.

High-Content Screening and Cell-Based Drug Discovery: 3D Models Reset the Assay Standard

High-content fluorescence imaging is increasingly being applied to 3D tumor spheroids, organoids, and organ-on-chip models. Compared with conventional 2D cell cultures, these models require more sophisticated imaging capabilities. A 2025 Nature Communications study is expected to report that the HCS-3DX platform delivers single-cell resolution in coculture tumor models and demonstrates how AI-guided 3D screening can improve the consistency of high-content screening. These workflows require specialized plates, reagents, and microfluidic chambers in addition to imaging instruments. Consequently, consumables and software are becoming increasingly important in the fluorescence cells Market.

High Capital and Lifecycle Cost: Access Asymmetry Shapes Market Geography

High-end fluorescence systems typically cost between USD 200,000 and more than USD 1 million. In addition, service agreements, laser replacements, and reagent expenses can add 10%-20% of the list price annually. Consequently, total ownership costs over a five-year period can significantly exceed the initial capital investment. This cost burden is particularly pronounced in South America, the Middle East, and Africa, where research budgets may not accommodate high-cost instruments. Shared-use facilities and instrument-as-a-service models can help expand access beyond major research centers. However, the need for trained operators, reproducible methodologies, and clinical validation further increases implementation costs and may constrain adoption in the fluorescence cells market.

Other drivers and restraints analyzed in the detailed report include:

1. Oncology, Infectious-Disease and Immunology Workflows: Multi-Disease Burden Expands the Addressable Base
2. AI-Enabled Image Analysis and Laboratory Automation: The Operator Bottleneck Is Being Structurally Resolved
3. Photobleaching, Phototoxicity and Autofluorescence: Illumination Intensity Limits Live-Cell and Tissue Workflows

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Fluorescence microscopes are projected to account for 37.5% of the fluorescence cells market revenue in 2025. Academic laboratories, pharmaceutical preclinical facilities, and hospital pathology departments widely use these instruments. Their leading position reflects a well-established installed base and broad applicability across cell biology, oncology, and neuroscience research. Product offerings range from entry-level benchtop instruments to confocal and super-resolution systems, allowing suppliers to address laboratories with varying technical requirements and capital budgets.

Fluorescence-activated cell sorters remain a high-value product category in the fluorescence cells market, particularly as cell therapy manufacturing increasingly requires controlled sorting and quality-control workflows. Fluorescence imaging systems also play an important role in spatial biology and drug discovery programs. In addition, probes and dyes generate recurring purchases across these instrument categories.

Accessories and consumables are forecast to grow at a CAGR of 8.6% through 2031, making them the fastest-growing product group in the fluorescence cells market. Growth is supported by the expanding installed base, as complex experiments require recurring purchases of reagents, plates, and related supplies. Automated imaging systems further integrate imaging stages, incubation, liquid handling, and analysis tools, creating continued demand for compatible reagents and software.

Thermo Fisher Scientific launched the Invitrogen EVOS S1000 Spatial Imaging System in February 2025. The system is designed to capture up to nine fluorescent targets simultaneously while supporting broad reagent compatibility. This capability links capital equipment sales with ongoing reagent demand. Suppliers can leverage compatible consumables to establish recurring revenue streams after the initial system sale.

Fluorescence lifetime imaging microscopy (FLIM) is projected to hold 31.7% of market revenue in 2025. Its market position reflects its analytical depth and ability to distinguish autofluorescence from probe signals without chemical pretreatment. This capability is valuable in tissue samples where endogenous signals can interfere with conventional intensity-based methods. Confocal microscopy remains widely adopted due to its optical sectioning, multichannel detection, and established protocols.

Multispectral imaging is gaining traction as AI-based unmixing improves spectral separation in the fluorescence cells market. Quantum dots also remain relevant for long-duration live-cell experiments due to their photostability. Together, these technologies address distinct requirements for resolution, throughput, and signal quality. As a result, the fluorescence cells market comprises multiple technology pathways rather than a single replacement cycle.

Super-resolution microscopy is forecast to grow at a CAGR of 7.8% through 2031. STED, STORM, and PALM technologies have progressed beyond specialist physics laboratories and are now available through commercial platforms. A 2025 Nature Biotechnology study evaluated CombPlex, which reconstructed 22-protein imaging panels from five imaging channels using combinatorial staining and deep learning. The approach increased the information density available from each experiment and demonstrated the potential of advanced imaging to support multiplexed biological analysis.

Carl Zeiss Microscopy is expected to receive a U.S. patent in July 2026 for a broadband-excitation fluorescence microscope. The patent indicates continued proprietary development across clinical and research imaging applications. However, super-resolution systems continue to face phototoxicity and photobleaching challenges in demanding live-cell applications.

Complete Report Scope:

• By Product Type
  • Fluorescence Microscopes
  • Fluorescence Activated Cell Sorters (FACS)
  • Fluorescence Imaging Systems
  • Fluorescent Probes and Dyes
  • Accessories and Consumables
• By Technology
  • Super-Resolution Microscopy
  • Fluorescence Lifetime Imaging Microscopy (FLIM)
  • Confocal Microscopy
  • Multispectral Imaging
  • Quantum Dot Technology
  • Other Technologies
• By Application
  • Cell Biology
  • Clinical Diagnostics
  • Pharmaceutical Research
  • Other Applications
• By End User
  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Hospitals and Diagnostic Laboratories
  • Other End Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America is projected to account for a 41.7% share of the fluorescence cells market in 2025. The region benefits from a strong concentration of academic medical centers, National Institutes of Health (NIH)-funded research infrastructure, and commercial biopharmaceutical activity. Federal instrumentation grants and academic hospital capital budgets support system procurement, while instrument-as-a-service models enable laboratories to upgrade installed equipment. Close collaboration between suppliers, reagent providers, and major research clusters further strengthens the regional ecosystem. These factors support demand for imaging, sorting, analysis software, and consumables. Canada's genomics and precision medicine networks also contribute to demand in the fluorescence cells market. [Source: NIH.gov]

Europe has a well-balanced demand base across academic research, clinical diagnostics, and pharmaceutical applications. Germany, the United Kingdom, France, and the Netherlands represent the most active national markets in the analysis. Multi-year research consortia facilitate coordinated equipment upgrades across university networks. Carl Zeiss AG is expected to introduce the Axioscan 7 Clinical in July 2026 for routine clinical diagnostic settings. The system will support transmitted-light, brightfield, and fluorescence modalities, with multiple magnification and z-stacking options. This development underscores the growing importance of validated clinical workflows in Europe. Sartorius is also targeting cell therapy manufacturing through its Eveo Cell Therapy Platform. Consequently, Europe combines sustained research demand with increasing requirements for analysis in regulated production environments.

Asia-Pacific is forecast to grow at a CAGR of 7.7% through 2031, making it the fastest-growing region in the fluorescence cells market. China's state-supported biomedical research infrastructure and genomics programs support purchases by academic hospitals and contract research organizations. In India, pharmaceutical manufacturing and contract research activities drive demand for identity and purity testing tools. Japan contributes significant precision optics capabilities through Hamamatsu Photonics, Nikon, Olympus, and Shimadzu. Japanese universities also deploy advanced platforms for regenerative medicine and materials science research. South America and the Middle East and Africa remain at earlier stages of adoption. Brazil and Gulf Cooperation Council research centers serve as the key demand anchors; however, infrastructure gaps and import dependence continue to limit the pace of procurement.

1. Agilent Technologies
2. Beckton Dickinson
3. Bio-Rad Laboratories
4. Bio-Techne
5. Bruker
6. Carl Zeiss
7. Cytek Biosciences, Inc.
8. Danaher
9. Hamamatsu Photonics
10. Hellma GmbH and Co. KG
11. HORIBA
12. Merck
13. Miltenyi Biotec
14. Nikon
15. Olympus
16. Oxford Instruments
17. PerkinElmer
18. Revvity, Inc.
19. Shimadzu
20. Starna Scientific Ltd.
21. Tecan Group
22. Thermo Fisher Scientific

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope Of The Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Biomedical Research and Diagnostic Adoption
  • 4.2.2 Oncology, Infectious-Disease and Immunology Workflows
  • 4.2.3 High-Content Screening and Cell-Based Drug Discovery
  • 4.2.4 Multiplexed Spectral and Spatial Cell Analysis
  • 4.2.5 AI-Enabled Image Analysis and Laboratory Automation
  • 4.2.6 Cell and Gene Therapy Characterization
• 4.3 Market Restraints
  • 4.3.1 High Capital and Lifecycle Cost
  • 4.3.2 Photobleaching, Phototoxicity and Autofluorescence
  • 4.3.3 Skilled-Operator and Quantitative-Analysis Gap
  • 4.3.4 Reproducibility, Interoperability and Clinical-Validation Burden
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat Of New Entrants
  • 4.7.2 Bargaining Power Of Buyers
  • 4.7.3 Bargaining Power Of Suppliers
  • 4.7.4 Threat Of Substitutes
  • 4.7.5 Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Fluorescence Microscopes
  • 5.1.2 Fluorescence Activated Cell Sorters (FACS)
  • 5.1.3 Fluorescence Imaging Systems
  • 5.1.4 Fluorescent Probes and Dyes
  • 5.1.5 Accessories and Consumables
• 5.2 By Technology
  • 5.2.1 Super-Resolution Microscopy
  • 5.2.2 Fluorescence Lifetime Imaging Microscopy (FLIM)
  • 5.2.3 Confocal Microscopy
  • 5.2.4 Multispectral Imaging
  • 5.2.5 Quantum Dot Technology
  • 5.2.6 Other Technologies
• 5.3 By Application
  • 5.3.1 Cell Biology
  • 5.3.2 Clinical Diagnostics
  • 5.3.3 Pharmaceutical Research
  • 5.3.4 Other Applications
• 5.4 By End User
  • 5.4.1 Academic and Research Institutes
  • 5.4.2 Pharmaceutical and Biotechnology Companies
  • 5.4.3 Hospitals and Diagnostic Laboratories
  • 5.4.4 Other End Users
• 5.5 Geography
  • 5.5.1 North America
    • 5.5.1.1 United States
    • 5.5.1.2 Canada
    • 5.5.1.3 Mexico
  • 5.5.2 Europe
    • 5.5.2.1 Germany
    • 5.5.2.2 United Kingdom
    • 5.5.2.3 France
    • 5.5.2.4 Italy
    • 5.5.2.5 Spain
    • 5.5.2.6 Rest of Europe
  • 5.5.3 Asia-Pacific
    • 5.5.3.1 China
    • 5.5.3.2 Japan
    • 5.5.3.3 India
    • 5.5.3.4 Australia
    • 5.5.3.5 South Korea
    • 5.5.3.6 Rest of Asia-Pacific
  • 5.5.4 Middle East and Africa
    • 5.5.4.1 GCC
    • 5.5.4.2 South Africa
    • 5.5.4.3 Rest of Middle East and Africa
  • 5.5.5 South America
    • 5.5.5.1 Brazil
    • 5.5.5.2 Argentina
    • 5.5.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(Includes Global Level Overview, Market Level Overview, Core Segments, Financials As Available, Strategic Information, Market Rank/Share For Key Companies, Products & Services, And Recent Developments)}
  • 6.3.1 Agilent Technologies, Inc.
  • 6.3.2 Becton, Dickinson and Company
  • 6.3.3 Bio-Rad Laboratories, Inc.
  • 6.3.4 Bio-Techne Corporation
  • 6.3.5 Bruker Corporation
  • 6.3.6 Carl Zeiss AG
  • 6.3.7 Cytek Biosciences, Inc.
  • 6.3.8 Danaher Corporation
  • 6.3.9 Hamamatsu Photonics K.K.
  • 6.3.10 Hellma GmbH and Co. KG
  • 6.3.11 HORIBA, Ltd.
  • 6.3.12 Merck KGaA
  • 6.3.13 Miltenyi Biotec GmbH
  • 6.3.14 Nikon Corporation
  • 6.3.15 Olympus Corporation
  • 6.3.16 Oxford Instruments plc
  • 6.3.17 PerkinElmer Inc.
  • 6.3.18 Revvity, Inc.
  • 6.3.19 Shimadzu Corporation
  • 6.3.20 Starna Scientific Ltd.
  • 6.3.21 Tecan Group Ltd.
  • 6.3.22 Thermo Fisher Scientific Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-Space & Unmet-Need Assessment